US › Healthcare

Damora Therapeutics, Inc. (DMRA)

US · Healthcare · Biotechnology

$30.02+5.11%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-27.8M

Profit YoY

-996.8%

EPS

$-0.81

EPS estimate

$-0.65

EPS came in at -0.81 against a street estimate of -0.65 — a miss of 24.6%.

Key statistics

Market cap

$1.76B

Forward P/E

0.0

P/B

4.71

Book value

$6.29

EPS (TTM)

$-2.68

52-week high

$38.33

52-week low

$2.45

50-day MA

$25.95

200-day MA

$23.76

Beta

1.48

Analyst view

with an average price target of $44.67.

Shareholding

Insiders

7.62%

Institutions

94.15%

Largest institutional holders

Fund	Stake
FMR Inc	15.00%
Fairmount Funds Management LLC	14.45%
venBio Select Advisor LLC	6.27%
VR Adviser, LLC	5.98%
FCPM III SERVICES BV	4.05%
RA Capital Management, LLC	3.98%
HHG PLC	3.92%
Viking Global Investors LP	3.83%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Damora Therapeutics, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.